D75.839 is a valid billable ICD-10 diagnosis code for Thrombocytosis, unspecified . It is found in the 2022 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2021 - Sep 30, 2022 . The use of ICD-10 code D75.839 can also apply to:
Thrombocytosis (or thrombocythemia) is often described as secondary or reactive, in which another disease, condition, or outside factor causes the high platelet count. Treatment and outlook for secondary thrombocytosis depend on the...
New subcategory D75.83, Thrombocytosis, has been created to separately identify other thrombocytosis, including secondary thrombocytosis and reactive thrombocytosis (D75.838) and unspecified thrombocytosis (D75.839).
Thrombocythemia and thrombocytosis are characterized by an abnormally high platelet count in the blood. Thrombocytosis (or thrombocythemia) is often described as secondary or reactive, in which another disease, condition, or outside factor causes the high platelet count.
ICD-10 code D75. 839 for Thrombocytosis, unspecified is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
An increased number of thrombocytes (platelets) in the blood, without a known cause. Clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
Other secondary thrombocytopenia D69. 59 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D69. 59 became effective on October 1, 2021.
Thrombocythemia refers to a high platelet count that is not caused by another health condition. This condition is sometimes called primary or essential thrombocythemia. Thrombocytosis refers to a high platelet count caused by another disease or condition.
Primary thrombocytosis (or essential thrombocythemia) is a single disease entity, with unique clinical characteristics. Thrombocytopenia is the medical term for a low blood platelet count. Platelets (thrombocytes) are colorless blood cells that play an important role in blood clotting.
A positive JAK2 V617F mutation test, along with other supporting clinical signs, means it is likely that the person tested has an MPN. Other testing, such as a bone marrow biopsy, may need to be performed to determine which MPN the person has and to evaluate its severity.
2022 ICD-10-CM Diagnosis Code D75. 83: Thrombocytosis.
The ITP Syndrome ITP is an autoimmune bleeding disorder caused by various etiologies, which is characterized by increased platelet destruction and impaired production, resulting in a decreased platelet count. Primary ITP is idiopathic, whereas secondary ITP is linked to an underlying condition (1).
Overview. Essential thrombocythemia (throm-boe-sie-THEE-me-uh) is an uncommon disorder in which your body produces too many platelets. Platelets are the part of your blood that sticks together to form clots. This condition may cause you to feel fatigued and lightheaded and to experience headaches and vision changes.
A normal platelet count ranges from 150,000 to 450,000 platelets per microliter of blood. Having more than 450,000 platelets is a condition called thrombocytosis; having less than 150,000 is known as thrombocytopenia. You get your platelet number from a routine blood test called a complete blood count (CBC).
Even though the platelet count is elevated for a short time (or even indefinitely after splenectomy), secondary thrombocytosis does not typically lead to abnormal blood clotting. Primary thrombocytosis, or essential thrombocythemia, can cause serious bleeding or clotting complications.
Scientific literature sometimes excludes thrombocytosis from the scope of thrombophilia by definition, but practically, by the definition of thrombophilia as an increased predisposition to thrombosis, thrombocytosis (especially primary thrombocytosis) is a potential cause of thrombophilia.